HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Givaudan

This article was originally published in The Rose Sheet

Executive Summary

Fragrance and flavors supplier inaugurates new multipurpose plant for manufacturing of complex specialty ingredients discovered by the company's global fragrance research team in Dubendorf, Switzerland. Plant marks a "turning point" in strategy for Givaudan's fragrance ingredients business, signaling a move away from manufacturing commodity chemicals such as sunscreen filters to focus on producing molecules for "innovative and proprietary specialties," company notes. Project represents a quarter of the total annual investment of the fragrance division, firm adds. Earlier this year, Givaudan ended seven-year UV filter manufacturing relationship with Roche (1"The Rose Sheet" Jan. 20, 2003, In Brief). Separately, the firm announced hiring of Caroline Sabas as a perfumer. Sabas most recently worked for Fragrance Resources...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel